These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36922805)

  • 1. Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial.
    Yang J; Huang A; Yang K; Jiang K
    BMC Cancer; 2023 Mar; 23(1):249. PubMed ID: 36922805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial).
    Ding C; Guo Y; Zhou Y; He Y; Chen C; Zhang M; Guo X
    BMC Cancer; 2023 Dec; 23(1):1237. PubMed ID: 38102553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
    BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
    He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
    Front Immunol; 2022; 13():853922. PubMed ID: 35720312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy.
    Kong Y; Su M; Fang J; Chen M; Zheng C; Jiang Y; Tao K; Wang C; Qiu G; Ji Y; Wang Y; Yang Y
    Sci Rep; 2024 Jul; 14(1):16495. PubMed ID: 39019976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
    Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
    BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol.
    Chen M; Huang Y; Zhang S; Zeng T; Huang G; Chen C; Zheng B
    Trials; 2023 Aug; 24(1):554. PubMed ID: 37626367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
    Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z
    BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
    Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J
    JAMA Surg; 2021 Aug; 156(8):721-729. PubMed ID: 34160577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.
    Zhang Z; Ye J; Li H; Gu D; Du M; Ai D; Chen W; Fang Y; Xu X; Bai C; Zhao K; Zhou G
    Front Immunol; 2022; 13():1031171. PubMed ID: 36311804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
    Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
    BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
    von Döbeln GA; Klevebro F; Jacobsen AB; Johannessen HO; Nielsen NH; Johnsen G; Hatlevoll I; Glenjen NI; Friesland S; Lundell L; Yu J; Nilsson M
    Dis Esophagus; 2019 Feb; 32(2):. PubMed ID: 30137281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study.
    Guo JC; Huang TC; Kuo HY; Lin CC; Hsu FM; Cheng JC; Huang YL; Hsieh MS; Huang PM; Lee JM; Wu SL; Hsu CH
    Cancer Immunol Immunother; 2024 Sep; 73(11):230. PubMed ID: 39249605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
    JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
    Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
    Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.
    Messager M; Mirabel X; Tresch E; Paumier A; Vendrely V; Dahan L; Glehen O; Vasseur F; Lacornerie T; Piessen G; El Hajbi F; Robb WB; Clisant S; Kramar A; Mariette C; Adenis A
    BMC Cancer; 2016 May; 16():318. PubMed ID: 27194176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
    Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
    Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design.
    Zheng Y; Li C; Yu B; Zhao S; Li J; Chen X; Li H
    JTCVS Open; 2022 Mar; 9():293-299. PubMed ID: 36003437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.